Clinical trial
Rosiglitazone to Treat Patients With Heart Failure and Glucose Intolerance or…
NCT00064727 · National Heart, Lung, and Blood Institute (NHLBI), NIH · Completed
Key facts
| NCT number | NCT00064727 |
|---|---|
| Title | Rosiglitazone to Treat Patients With Heart Failure and Glucose Intolerance or Type II Diabetes |
| Official title | Attenuating Insulin Resistance as a Therapeutic Target in the Management of Heart Failure |
| Lead sponsor | National Heart, Lung, and Blood Institute (NHLBI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Congestive Heart Failure |
| Intervention type | Drug |
| Interventions | Avandia (Rosiglitazone), Avanclia (Rosiqlitazone) |
| Enrollment | 50 |
| Start date | Jul 9, 2003 |
| Completion | Apr 11, 2007 |
| First posted | Jul 11, 2003 |
| Last update posted | Jul 2, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: